XenTech remains fully operational after 7 weeks of COVID-19 pandemic : update from our COO
Dear valued customers
In this 7th week of containment and as end of confinement in France is announced for May 11th, I would first of all like to thank you on behalf of our teams for all the messages of support you have sent us since the beginning of the COVID-19 crisis.
From the start of the pandemic, our top priority has been to take the necessary measures to ensure the safety of our employees.
We also have reorganized the operations of the entire company in order to continue to provide all our services with the same level of quality that you always expected from us. These measures evolve whenever necessary, according to the situation and the directives of our national authorities, but thanks to the unfailing commitment of our teams, whom I cannot thank enough, we continue to provide you with the results you need for the advancement of your projects, with quality level you legitimately expect. All the studies are proceeding as planned and we are fully maintaining our capacity to initiate new ones.
We are grateful for your continued support during this period. We hope that you and your loved ones are all safe and healthy.
We are listening to the new government guidelines but can already assure you that we have the capacity to continue to provide our services until we return to normal daily life.
Please do not hesitate to ask our scientists to evaluate how we can help you with your research projects.
Yours faithfully,
Pascal Leuraud, COO
Regarding the current circumstances, we at XenTech want you to know that we are taking the Covid-19 pandemia very seriously. We are closely monitoring the pandemic, following guidance and advice from the World Health Organization (WHO), and the French Government.
Our top priority will remain our employees’ health but we wish to reassure you that, thanks to the energy and efforts of our teams, we have the ability to remain operational and ensure the continuity of our services.
Below is an update on our plans, and how we are managing operations during this unusual time.
- Our continuity plan has been reviewed to adapt to the current context.
- Sick and work-from-home (whenever possible) policies are already into force.
- Critical animal related activities, including customer studies, will be maintained even in a situation where employee absenteeism is increased temporarily.
- Animal related operation already requires the wearing of protective equipment (Tyvek overalls, FFP2 masks, latex/nitrile gloves, headgear), protecting animals from pathogens but also preventing employees from contamination.
- Hygiene and containment best practices (according to the WHO and the French Government) are applied and regularly repeated to employees.
- Business travel and meetings attendance is and will remain strictly limited for all XenTech personnel until further notice.
XenTech will continue to adapt to new guidelines from the WHO and the French Government and keep you informed of additional measures.
XenTech is proud to fight any pediatric cancers types !
In our continuous effort to fight any pediatric cancer type, Stefano Cairo, XenTech’s Head of R&D, will present, together with Dr. Charles Keller from CC-TDI, a talk about Liver Cancer Tumor Models and Drug Discovery.
Agenda of this 2-day event : HERE
Free Registration – More information about this event can be found by clicking on this LINK
XenTech is proud to talk and present a poster at PARPi & DDR Summit in Boston soon…
Oral presentation : « Deciphering the DDR genetic landscape in human tumors using patient-derived experimental models »
Stefano Cairo, XenTech Head of R&D (Jan. 29, 11:35am)
XenTech Signs Strategic Collaboration Agreement with Gustave Roussy Cancer Center
Press-Release March 27, 2019
Click on the below immage to read the Press Release (PDF)
Xentech team will attend AACR annual meeting 2019 in Atlanta, GA from March 29th to April 4th. Come to visit us at booth #3444 to learn more about our latest PDX models and our associated services. Don’t forget to have a look at our posters and chat with our scientific team. See abstracts #5415, #4841 and #4878 for more details. See you there!
XenTech presents 7 posters at AACR 2018
|
Abstract Number: 919 Endogenous STING inhibition induces breast cancer cell death Date and Time: Sunday Apr 15, 2018; 1:00 PM – 5:00 PM Location: Poster Section 41 Poster Board Number: 26 A current cancer immunotherapy strategy proposes the use of STING agonists to boost the patient’s immune system through the cytokine-mediated enhancement of tumor infiltration and killing by immune cells. Using breast cancer cell lines including those derived from patient-derived xenografts, we show that STING clustering at DNA breaks in the nucleus is a general feature of breast cancer cells exposed to genotoxic agents, and that the STING pathway is a cell-intrinsic mechanism of cell survival. This study points up potentially antagonistic effects of STING pathway manipulation in tumor control. |
Abstract Number: 2147 Development of preclinical models to accelerate the identification of next generation treatments for patients with acquired resistance to targeted therapies Date and Time: Monday Apr 16, 2018; 1:00 PM – 5:00 PM Location: Poster Section 7 Poster Board Number: 2 Patients whose tumor harbor specific driver molecular alterations benefit from targeted therapies but responses are generally short-lived due to the emergence of adaptive/secondary resistance. The MATCH-R trial led by Gustave Roussy, Villejuif, France (NCT02517892) will enroll 600 patients treated with targeted therapies. Biopsies obtained from 300 patients at resistance will be used to develop PDX models. This first report features PDX models with acquired resistance to last-generation therapies such as osimertinib, erdafitinib or trametinib. The MATCH-R PDX platform is being regularly upgraded with new models, providing a unique resource to unravel the mechanisms involved in acquired resistance to targeted therapies and develop novel therapeutic strategies translating into increased patient survival. |
|
Abstract Number: 2811 High IFN/STAT-related gene expression is associated with sensitivity to PARP inhibitors of triple negative breast cancer Date and Time: Monday Apr 16, 2018; 1:00 PM – 5:00 PM Location: Poster Section 37 Poster Board Number: 1 Pathogenic BRCA1/2 mutations and other genomic alterations are hallmarks of cancers with homologous recombination deficiency (HRD) that are more likely to be sensitive to PARP inhibitors (PARPi). However, these markers lack specificity as less than half of patients harboring BRCA-mutated or HRD-positive tumors are responsive to PARP inhibitors, and a number of tumors without BRCA1/2 mutations are responsive to PARPis. In vivo efficacy of PARPis was tested in a panel of 53 TNBC PDX models characterized for BRCA1/2 or HRD status and a gene expression classifier was built that improved the accuracy of the BRCA and HRD assays in predicting PARPi responsiveness. |
Abstract Number: 4628 Tailoring personalized strategies for children with treatment-refractory liver cancer Date and Time: Tuesday Apr 17, 2018; 1:00 PM – 5:00 PM Location: Poster Section 29 Poster Board Number: 1 Hepatoblastoma (HB) is a rare paediatric tumor for which it is difficult to set up clinical trials. We developed a panel of 24 HB PDX models and 10 corresponding PDX-derived cell lines as a translational platform for the development of novel therapeutic options for children with HB. Here we show that volasertib, an inhibitor of the PLK1 oncogene that is overexpressed in HB, displays a good efficacy profile, comparable to that of the temozolomide/irinotecan combination. |
|
Abstract Number: 5600 Establishment and characterization of a unique circulating tumor cells-derived xenograft (CDX) in prostate cancer Date and Time: Wednesday, April 18; 8:00 AM-12:00 PM Location: Poster Section 27 Poster Board Number: 3 We report the development of a unique PDX model from the CTCs of a patient with advanced prostate cancer (PCa). While demonstrating the tumorigenicity of CTCs from PCa, this CDX model represents a unique tool to identify clonal mutations associated with the tumor-initiating capacity of CTCs and explore the genetic and phenotypic basis of metastasis and drug resistance in advanced PCa. |
Abstract Number: 1718 Tumor immune gene profile before and after various targeted therapies in NSCLC PDXs Date and Time: Monday Apr 16, 2018; 8:00 AM – 12:00 AM Location: Poster Section 32 Poster Board Number: 13 Using a panel of non-humanized NSCLC PDXs, we have identified specific tumor immune profiles and a set of genes involved in the response to targeted therapies. Pharmacodynamic analysis of immune markers reveals potential combinations of targeted therapies with immune checkpoints blockade that may have important translational value. |
Abstract Number: 2597
Development and characterization of novel non-small cell lung cancer (NSCLC) circulating tumor cells (CTCs)-derived xenograft (CDX) models
Date and Time: Monday Apr 16, 2018 1:00 PM – 5:00 PM
Location: Poster Section 25
Poster Board Number: 27
We describe the establishment and characterization of 4 CDX models from advanced NSCLC patients. This study revealed both similarities and differences between CDXs and their corresponding patient tumor biopsies. These NSCLC CDX models represent unique tools to identify clonal mutations associated with the tumor-initiating capacity of CTCs and explore the genetic and phenotypic basis of metastasis and drug resistance associated with advanced NSCLC.
XenTech launches a new line of PDX models of acquired resistance to last generation targeted therapies
Development of 75 PDX models from patients with acquired resistance to latest targeted drugs
A preclinical platform to identify resistance mechanisms and develop new therapeutic strategies
Background: Patients whose tumor harbor specific driver molecular alterations benefit from targeted therapies. These molecules have a good efficacy profile but patients’ responses are generally short-lived due to the emergence of adaptive/secondary resistance. Disposing of clinically relevant models to identify the resistance mechanisms at play and perform preclinical POC studies is critical to develop new therapeutic strategies translating into increased patient survival.
Outline:
The MATCH-R precision medicine trial led by Gustave Roussy (NCT02517892) will enroll 600 patients treated with targeted therapies in phase I/II studies between 2014 and 2020. Its main goal is to study the molecular evolution of tumors subjected to targeted therapies and developing acquired resistance.
Biopsies from progressing tumor lesions will be performed in 300 patients having developed resistance following initial response and used to generate PDX models that will be expanded under therapy to confirm their resistance status and molecularly characterized by WES and RNAseq.
Click images below for
Already available Models Models in Development for 2018
LinkedIn
Twitter
